Hedera Dx provides a liquid biopsy solution that enables hospital laboratories to perform CE-IVDR compliant tumor profiling in-house using circulating tumor DNA (ctDNA). Their integrated software and assay panel streamline the workflow from blood draw to clinical reporting for personalized oncology treatment selection. This platform simplifies the adoption of NGS-based liquid biopsies, offering actionable insights for patient care.
Funding
$14M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional tissue biopsies for tumor profiling can be infeasible or fail in a significant percentage of cancer patients, limiting their access to personalized treatment options. Existing NGS-based liquid biopsy workflows face challenges related to assay validation, regulatory compliance, complex bioinformatics, and limited clinical evidence for in-house molecular testing.
Solution
Hedera Dx offers a liquid biopsy solution that enables hospital laboratories to perform in-house tumor profiling using circulating tumor DNA (ctDNA) from a simple blood draw. The solution includes Hedera Prime, a CE-IVD medical device software, and Hedera Profiling 2 ctDNA test panel, a pan-cancer targeted assay. This integrated approach streamlines the biopsy process, allowing for the generation of clinical reports with regulatory-approved therapy options based on the patient's tumor ctDNA sequence. By simplifying the integration of liquid biopsies into existing laboratory settings, Hedera Dx expands treatment options for patients and facilitates personalized cancer care.
Target Audience
The primary target audience includes hospital laboratories, molecular pathology departments, and clinical oncologists seeking to implement in-house liquid biopsy testing for personalized cancer treatment.
Features
- CE-IVDR compliant liquid biopsy solution for in-house tumor profiling
- Hedera Prime software for streamlined workflow and reporting
- Hedera Profiling 2 ctDNA test panel, a pan-cancer targeted assay
- NGS-based analysis of ctDNA extracted from a simple blood draw
- Clinical report generation with regulatory-approved therapy options
- Integration into existing molecular pathology laboratory settings
- Participation in the EMPATHY NSCLC study for real-world clinical validation